1
|
He Y, Martin AR. We need more-diverse biobanks to improve behavioural genetics. Nat Hum Behav 2024; 8:197-200. [PMID: 38158402 DOI: 10.1038/s41562-023-01795-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2024]
Affiliation(s)
- Yixuan He
- Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, USA
- Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA, USA
- Analytic and Translational Genetics Unit, Massachusetts General Hospital, Boston, MA, USA
| | - Alicia R Martin
- Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
- Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
- Analytic and Translational Genetics Unit, Massachusetts General Hospital, Boston, MA, USA.
| |
Collapse
|
2
|
Bettio V, Mazzucco E, Aleni C, Cracas S, Rinaldi C, Antona A, Varalda M, Venetucci J, Ferrante D, Rimedio A, Capello D. UPO Biobank: The Challenge of Integrating Biobanking into the Academic Environment to Support Translational Research. J Pers Med 2023; 13:911. [PMID: 37373900 DOI: 10.3390/jpm13060911] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/05/2023] [Revised: 05/18/2023] [Accepted: 05/26/2023] [Indexed: 06/29/2023] Open
Abstract
Biobanks are driving motors of precision and personalized medicine by providing high-quality biological material/data through the standardization and harmonization of their collection, preservation, and distribution. UPO Biobank was established in 2020 as an institutional, disease, and population biobank within the University of Piemonte Orientale (UPO) for the promotion and support of high-quality, multidisciplinary studies. UPO Biobank collaborates with UPO researchers, sustaining academic translational research, and supports the Novara Cohort Study, a longitudinal cohort study involving the population in the Novara area that will collect data and biological specimens that will be available for epidemiological, public health, and biological studies on aging. UPO Biobank has been developed by implementing the quality standards for the field and the ethical and legal issues and normative about privacy protection, data collection, and sharing. As a member of the "Biobanking and Biomolecular Resources Research Infrastructure" (BBMRI) network, UPO Biobank aims to expand its activity worldwide and launch cooperation with new national and international partners and researchers. The objective of this manuscript is to report an institutional and operational experience through the description of the technical and procedural solutions and ethical and scientific implications associated with the establishment of this university research biobank.
Collapse
Affiliation(s)
- Valentina Bettio
- UPO Biobank, University of Piemonte Orientale, 28100 Novara, Italy
- Department of Translational Medicine, Center of Excellence in Aging Sciences, University of Piemonte Orientale, 28100 Novara, Italy
| | - Eleonora Mazzucco
- UPO Biobank, University of Piemonte Orientale, 28100 Novara, Italy
- Department of Translational Medicine, Center of Excellence in Aging Sciences, University of Piemonte Orientale, 28100 Novara, Italy
| | - Chiara Aleni
- Department of Sustainable Development and Ecological Transition, University of Piemonte Orientale, 13100 Vercelli, Italy
| | - Silvia Cracas
- Department of Translational Medicine, Center of Excellence in Aging Sciences, University of Piemonte Orientale, 28100 Novara, Italy
| | - Carmela Rinaldi
- Department of Translational Medicine, Center of Excellence in Aging Sciences, University of Piemonte Orientale, 28100 Novara, Italy
- Learning and Research Area, A.O.U. Maggiore della Carità, 28100 Novara, Italy
| | - Annamaria Antona
- Department of Translational Medicine, Center of Excellence in Aging Sciences, University of Piemonte Orientale, 28100 Novara, Italy
| | - Marco Varalda
- Department of Translational Medicine, Center of Excellence in Aging Sciences, University of Piemonte Orientale, 28100 Novara, Italy
| | - Jacopo Venetucci
- Department of Translational Medicine, Center of Excellence in Aging Sciences, University of Piemonte Orientale, 28100 Novara, Italy
| | - Daniela Ferrante
- Department of Translational Medicine, Center of Excellence in Aging Sciences, University of Piemonte Orientale, 28100 Novara, Italy
| | - Antonio Rimedio
- Ethics Committee of the University "Hospital Major of Charity" in Novara, Local Health Authorities Biella, 28100 Novara, Italy
| | - Daniela Capello
- UPO Biobank, University of Piemonte Orientale, 28100 Novara, Italy
- Department of Translational Medicine, Center of Excellence in Aging Sciences, University of Piemonte Orientale, 28100 Novara, Italy
| |
Collapse
|
3
|
Boutin NT, Schecter SB, Perez EF, Tchamitchian NS, Cerretani XR, Gainer VS, Lebo MS, Mahanta LM, Karlson EW, Smoller JW. The Evolution of a Large Biobank at Mass General Brigham. J Pers Med 2022; 12:jpm12081323. [PMID: 36013271 PMCID: PMC9410531 DOI: 10.3390/jpm12081323] [Citation(s) in RCA: 14] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2022] [Revised: 08/03/2022] [Accepted: 08/10/2022] [Indexed: 12/14/2022] Open
Abstract
The Mass General Brigham Biobank (formerly Partners HealthCare Biobank) is a large repository of biospecimens and data linked to extensive electronic health record data and survey data. Its objective is to support and enable translational research focused on genomic, environmental, biomarker and family history associations with disease phenotypes. The Biobank has enrolled more than 135,000 participants, generated genomic data on more than 65,000 of its participants, distributed approximately 153,000 biospecimens, and served close to 450 institutional studies with biospecimens or data. Although the Biobank has been successful, based on some measures of output, this has required substantial institutional investment. In addition, several challenges are ongoing, including: (1) developing a sustainable cost model that doesn’t rely as heavily on institutional funding; (2) integrating Biobank operations into clinical workflows; and (3) building a research resource that is diverse and promotes equity in research. Here, we describe the evolution of the Biobank and highlight key lessons learned that may inform other efforts to build biobanking efforts in health system contexts.
Collapse
Affiliation(s)
| | | | | | | | | | - Vivian S. Gainer
- Mass General Brigham Research Information Science & Computing, Boston, MA 02115, USA
| | - Matthew S. Lebo
- Mass General Brigham Personalized Medicine, Boston, MA 02115, USA
- Brigham and Women’s Hospital, Boston, MA 02115, USA
| | - Lisa M. Mahanta
- Mass General Brigham Personalized Medicine, Boston, MA 02115, USA
| | - Elizabeth W. Karlson
- Mass General Brigham Personalized Medicine, Boston, MA 02115, USA
- Brigham and Women’s Hospital, Boston, MA 02115, USA
- Correspondence: ; Tel.: +1-617-732-5078; Fax: +1-617-713-3030
| | - Jordan W. Smoller
- Mass General Brigham Personalized Medicine, Boston, MA 02115, USA
- Massachusetts General Hospital, Boston, MA 02114, USA
| |
Collapse
|
4
|
Economics of Biobanking: Business or Public Good? Literature Review, Structural and Thematic Analysis. SOCIAL SCIENCES-BASEL 2022. [DOI: 10.3390/socsci11070288] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
This paper reviewed the relevant scientific literature on the business and economics of biobanking to explore key themes and paradigms. The structural properties of the literature were investigated, such as key authors, journals, studies, as well as co-citation and co-authorship networks; the study revealed that the research on business and economics is a niche area within the vast biobanking literature. The research is concentrated in a relatively small number of journals, institutions, and countries, which is rather surprising given the substantial public investment in and concerns about biobank sustainability. The structural analysis also suggested major themes in research on biobanking business and economics and noted shifts in focus on specific themes. The commercialisation of samples is more acknowledged than before but under the condition of equitable sharing of benefits across various stakeholders. Most biobanks are heavily subsidised by the public sector and are considered public goods rather than business enterprises. This is OK, but underutilisation of specimens and low rates of cost recovery suggest that the current mainstream operating model is hardly sustainable. With many biobanks maturing, long-term sustainability became a key topic of the discussion on biobanking trends.
Collapse
|
5
|
Willers C, Lynch T, Chand V, Islam M, Lassere M, March L. A Versatile, Secure, and Sustainable All-in-One Biobank-Registry Data Solution: The A3BC REDCap Model. Biopreserv Biobank 2021; 20:244-259. [PMID: 34807733 DOI: 10.1089/bio.2021.0098] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022] Open
Abstract
Introduction: A key element in the big data revolution is large-scale biobanking and the associated development of high-quality data collections and supporting informatics solutions. As such, in establishing the Australian Arthritis and Autoimmune Biobank Collaborative (A3BC), we sought to establish a low-cost, nation-scale data management system capable of managing a multisite biobank registry with complex longitudinal sample and data requirements. Materials and Methods: We assessed several international commercial and nonprofit software platforms using standardized system requirement criteria and follow-up interviews. Vendor compliance scoring was prioritized to meet our project-critical requirements. Consumer/end-user codesign was integral to refining our system requirements for optimized adoption. Customization of the selected software solution was performed to optimize field auto-population between participant timepoints and forms, using modules that are transferable and that do not impact core code. Institutional and independent testing was used to ensure data security. Results: We selected the widely used research web application Research Electronic Data Capture (REDCap), which is "free" (under nonprofit license agreement terms), highly configurable, and customizable to a variety of biobank and registry needs and can be developed/maintained by biobank users with modest IT skill, time, and cost. We created a secure, comprehensive participant-centric biobank-registry database that includes: (1) best practice data security measures (incl. multisite access login using institutional user credentials), (2) permission-to-contact and dynamic itemized electronic consent, (3) a complete chain of custody from consent to longitudinal biospecimen data collection to publication, (4) complex longitudinal patient-reported surveys, (5) integration of record-level extracted/linked participant data, (6) significant form auto-population for streamlined data capture, and (7) native dashboards for operational visualizations. Conclusion: We recommend the versatile, reusable, and sustainable informatics model we have developed in REDCap for prospective chronic disease biobanks or registry biobanks (of local to national complexity) supporting holistic research into disease prediction, precision medicine, and prevention strategies.
Collapse
Affiliation(s)
- Craig Willers
- Institute of Bone and Joint Research, The Australian Arthritis and Autoimmune Biobank Collaborative, Kolling Institute, University of Sydney, Sydney, Australia
| | - Tom Lynch
- Institute of Bone and Joint Research, The Australian Arthritis and Autoimmune Biobank Collaborative, Kolling Institute, University of Sydney, Sydney, Australia
| | - Vibhasha Chand
- Public Health and Preventive Medicine, Monash University, Clayton, Australia
| | - Mohammad Islam
- Information and Communications Technology, University of Sydney, Sydney, Australia
| | - Marissa Lassere
- School of Population Health, University of New South Wales, Sydney, Australia
| | - Lyn March
- Institute of Bone and Joint Research, The Australian Arthritis and Autoimmune Biobank Collaborative, Kolling Institute, University of Sydney, Sydney, Australia
- Department of Rheumatology, Royal North Shore Hospital, St Leonards, Australia
| |
Collapse
|
6
|
Tegtmeyer M, Nehme R. Leveraging the Genetic Diversity of Human Stem Cells in Therapeutic Approaches. J Mol Biol 2021; 434:167221. [PMID: 34474087 DOI: 10.1016/j.jmb.2021.167221] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/06/2021] [Revised: 08/17/2021] [Accepted: 08/23/2021] [Indexed: 01/14/2023]
Abstract
Since their discovery 15 years ago, human pluripotent stem cell (hPSC) technologies have begun to revolutionize science and medicine, rapidly expanding beyond investigative research to drug discovery and development. Efforts to leverage hPSCs over the last decade have focused on increasing both the complexity and in vivo fidelity of human cellular models through enhanced differentiation methods. While these evolutions have fostered novel insights into disease mechanisms and influenced clinical drug discovery and development, there are still several considerations that limit the utility of hPSC models. In this review, we highlight important, yet underexplored avenues to broaden their reach. We focus on (i) the importance of diversifying existing hPSC collections, and their utilization to investigate therapeutic strategies in individuals from different genetic backgrounds, ancestry and sex; (ii) considerations for the selection of therapeutically relevant hPSC-based models; (iii) strategies to adequately increase the scale of cell-based studies; and (iv) the advances and constraints of clinical trials in a dish. Moreover, we advocate for harnessing the translational capabilities of hPSC models along with the use of innovative, scalable approaches for understanding genetic biases and the impact of sex and ancestry on disease mechanisms and drug efficacy and response. The next decade of hPSC innovation is poised to provide vast insights into the genetic basis of human disease and enable rapid advances to develop, repurpose, and ensure the safety of the next generation of disease therapies across diverse human populations.
Collapse
Affiliation(s)
- Matthew Tegtmeyer
- Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA 02138, USA; Centre for Stem Cells and Regenerative Medicine, King's College London, London, UK
| | - Ralda Nehme
- Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA 02138, USA.
| |
Collapse
|
7
|
van der Stijl R, Manders P, Eijdems EWHM. Recommendations for a Dutch Sustainable Biobanking Environment. Biopreserv Biobank 2021; 19:228-240. [PMID: 34042498 PMCID: PMC8217590 DOI: 10.1089/bio.2021.0011] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023] Open
Abstract
Biobanks and their collections are considered essential for contemporary biomedical research and a critical resource toward personalized medicine. However, they need to operate in a sustainable manner to prevent research waste and maximize impact. Sustainability is the capacity of a biobank to remain operative, effective, and competitive over its expected lifetime. This remains a challenge given a biobank's position at the interplay of ethical, societal, scientific, and commercial values and the difficulties in finding continuous funding. In the end, biobanks are responsible for their own sustainability. Still, biobanks also depend on their surrounding environment, which contains overarching legislative, policy, financial, and other factors that can either impede or promote sustainability. The Biobanking and Biomolecular Research Infrastructure for The Netherlands (BBMRI.nl) has worked on improving the national environment for sustainable biobanking. In this article, we present the final outcomes of this BBMRI.nl project. First, we summarize the current overarching challenges of the Dutch biobanking landscape. These challenges were gathered during workshops and focus groups with Dutch biobanks and their users, for which the full results are described in separate reports. The main overarching challenges relate to sample and data quality, funding, use and reuse, findability and accessibility, and the general image of biobanks. Second, we propose a package of recommendations—across nine themes—toward creating overarching conditions that stimulate and enable sustainable biobanking. These recommendations serve as a guideline for the Dutch biobanking community and their stakeholders to jointly work toward practical implementation and a better biobanking environment. There are undoubtedly parallels between the Dutch situation and the challenges found in other countries. We hope that sharing our project's approach, outcomes, and recommendations will support other countries in their efforts toward sustainable biobanking.
Collapse
Affiliation(s)
- Rogier van der Stijl
- University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.,UMCG Research BV, University Medical Center Groningen, Groningen, The Netherlands.,BBMRI.nl, Biobanking and Biomolecular Resources Research Infrastructure, The Netherlands
| | - Peggy Manders
- Radboud Biobank, Radboud University Medical Center, Nijmegen, The Netherlands
| | - Elisabeth W H M Eijdems
- University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.,BBMRI.nl, Biobanking and Biomolecular Resources Research Infrastructure, The Netherlands
| |
Collapse
|
8
|
Gramatiuk SM, Bagmut IY, Sheremet MI, Sargsyan K, Yushko AM, Filipchenko SM, Maksymyuk VV, Tarabanchuk VV, Moroz PV, Popovich AI. Pediatric biobanks and parents of disabled children associations opinions on establishing children repositories in developing countries. J Med Life 2021; 14:50-55. [PMID: 33767785 PMCID: PMC7982269 DOI: 10.25122/jml-2020-0106] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
Pediatric biobanks are an indispensable resource for the research needed to bring advances in personalized medicine into pediatric medical care. It is unclear how or when these advances in medical care may reach children, but it is unlikely that research in adults will be adequate. We conducted the screening for a hypothetic problem in various European and American pediatric biobanks based on online surveys through e-mail distribution based on the Biobank Economic Modeling Tool (BEMT) questionnaire model. Participants in the survey had work experience in biobanking for at least 3 years or more. Contact information about the survey participants was confirmed on the social networks profiles (LinkedIn), as well as on generally available websites. First, we tried creating a model which can show the pediatric preclinical and basic clinical phase relationship and demonstrate how pediatric biobanking is linked to this process. Furthermore, we tried to look for new trends, and the final goal is to put the acquired knowledge into practice, so medical experts and patients could gain usable benefit from it. We concluded that leading positions must take into account ethical and legal aspects when considering the decision to include children in the biobank collection. However, communication with parents and children is essential. The biobank characteristics influence the biobank's motives to include children in the consent procedure. Moreover, the motives to include children influence how the children are involved in the consent procedure and the extent to which children are able to make voluntary decisions as part of the consent procedure.
Collapse
Affiliation(s)
| | | | | | | | - Alla Mironovna Yushko
- Ukraine Association of Biobank, Institute of Cellular Biorehabilitation, Kharkiv, Ukraine.,Yaroslav Mudryi National Law University, Kharkiv, Ukraine
| | | | | | | | | | - Andriy Ivanovich Popovich
- Department of Pathology (Pathology and Forensic Medicine), Bukovinian State Medical University, Chernivtsi, Ukraine
| |
Collapse
|
9
|
Rush A, Catchpoole DR, Ling R, Searles A, Watson PH, Byrne JA. Improving Academic Biobank Value and Sustainability Through an Outputs Focus. VALUE IN HEALTH : THE JOURNAL OF THE INTERNATIONAL SOCIETY FOR PHARMACOECONOMICS AND OUTCOMES RESEARCH 2020; 23:1072-1078. [PMID: 32828220 DOI: 10.1016/j.jval.2020.05.010] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/14/2020] [Revised: 05/18/2020] [Accepted: 05/23/2020] [Indexed: 06/11/2023]
Abstract
Although it is generally accepted that human tissue biobanks are important to facilitate progress in health and medical research, many academic biobanks face sustainability challenges. We propose that biobank sustainability is challenged by a lack of available data describing the outputs and benefits that are produced by biobanks, as reflected by a dearth of publications that enumerate biobank outputs. We further propose that boosting the available information on biobank outputs and using a broader range of output metrics will permit economic analyses such as cost-consequence analyses of biobank activity. Output metrics and cost-consequence analyses can allow biobanks to achieve efficiencies, and improve the quality and/or quantity of their outputs. In turn, biobank output measures provide all stakeholders with explicit and accountable data on biobank value, which could contribute to the evolution of biobank operations to best match research needs, and mitigate some threats to biobank sustainability.
Collapse
Affiliation(s)
- Amanda Rush
- Discipline of Child and Adolescent Health, Sydney Medical School, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.
| | - Daniel R Catchpoole
- Children's Cancer Research Unit, Kids Research, The Children's Hospital at Westmead, Westmead, NSW, Australia
| | - Rod Ling
- Health Research Economics, Hunter Medical Research Institute, New Lambton Heights, NSW, Australia
| | - Andrew Searles
- Health Research Economics, Hunter Medical Research Institute, New Lambton Heights, NSW, Australia
| | - Peter H Watson
- Office of Biobank Education and Research, Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada
| | - Jennifer A Byrne
- NSW Health Statewide Biobank, NSW Health Pathology, Professor Marie Bashir Centre, Camperdown, NSW, Australia.
| |
Collapse
|
10
|
Cicek MS, Olson JE. Mini-Review of Laboratory Operations in Biobanking: Building Biobanking Resources for Translational Research. Front Public Health 2020; 8:362. [PMID: 32850593 PMCID: PMC7399165 DOI: 10.3389/fpubh.2020.00362] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2019] [Accepted: 06/24/2020] [Indexed: 01/05/2023] Open
Abstract
Biobanks have become integral to improving population health. We are in a new era in medicine as patients, health professionals, and researchers increasingly collaborate to gain new knowledge and explore new paradigms for diagnosing and treating disease. Many large-scale biobanking efforts are underway worldwide at the institutional, national, and even international level. When linked with subject data from questionnaires and medical records, biobanks serve as valuable resources in translational research. A biobank must have high quality samples that meet researcher's needs. Biobank laboratory operations require an enormous amount of support—from lab and storage space, information technology expertise, and a laboratory management information system to logistics for sample movement, quality management systems, and appropriate facilities. A paramount metric of success for a biobank is the concept of every biospecimen coming to the repository belongs to a participant who has something to contribute to research for a healthier future. This article will discuss the importance of biorepository operations, specific to the collection and storage of participants materials. Specific focus will be given to maintaining the quality of samples, along with the various levels of support biorepositories need to fulfill their purpose and ensure the integrity of each specimen is maintained.
Collapse
Affiliation(s)
- Mine S Cicek
- Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, United States
| | - Janet E Olson
- Department of Health Sciences Research, Mayo Clinic, Rochester, MN, United States
| |
Collapse
|
11
|
Sqalli H, El Awadi N, Rancati C. [Biobankonomics: the sustainability indicators of biobanks]. Med Sci (Paris) 2020; 36:282-285. [PMID: 32228851 DOI: 10.1051/medsci/2020043] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Affiliation(s)
- Hadi Sqalli
- MSc Biobanks and Complex Data Management, Université Côte d'Azur, Centre Hospitalier Universitaire de Nice, Hôpital Pasteur, Biobanque BB-0033-00025, Nice, France
| | - Nora El Awadi
- MSc Biobanks and Complex Data Management, Université Côte d'Azur, Centre Hospitalier Universitaire de Nice, Hôpital Pasteur, Biobanque BB-0033-00025, Nice, France
| | - Caroline Rancati
- MSc Biobanks and Complex Data Management, Université Côte d'Azur, Centre Hospitalier Universitaire de Nice, Hôpital Pasteur, Biobanque BB-0033-00025, Nice, France
| |
Collapse
|
12
|
Della Togna G, Howell LG, Clulow J, Langhorne CJ, Marcec-Greaves R, Calatayud NE. Evaluating amphibian biobanking and reproduction for captive breeding programs according to the Amphibian Conservation Action Plan objectives. Theriogenology 2020; 150:412-431. [PMID: 32127175 DOI: 10.1016/j.theriogenology.2020.02.024] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/11/2020] [Accepted: 02/16/2020] [Indexed: 01/18/2023]
Abstract
The Amphibian Conservation Action Plan (ACAP), published in 2007, is a formal document of international significance that proposed eleven relevant actions for global amphibian conservation. Action seven of the ACAP document addresses the use of amphibian captive programs as a conservation tool. Appendix material under this action explores the potential use of Genome Resource Banking (biobanking) as an urgently needed tool for these captive programs. ACAP proposed twelve objectives for Genome Resource Banking which exhibit little emphasis on reproduction as a vital underlying science for amphibian Captive Breeding Programs (CBP's). Here we have reassessed the original twelve ACAP objectives for amphibian reproduction and biobanking for CBP's as a contribution to future ACAP review processes. We have reviewed recent advances since the original objectives, as well as highlighted weaknesses and strengths for each of these objectives. We make various scientific, policy and economic recommendations based on the current reality and recent advances in relevant science in order to inform future ACAP towards new global objectives. The number of amphibian CBP'S has escalated in recent years and reproductive success is not always easily accomplished. Increases in applied and fundamental research on the natural history and reproductive biology of these species, followed by the appropriate development and application of artificial reproductive technologies (ART's) and the incorporation of genome resource banks (GRB's), may turn CBP's into a more powerful tool for amphibian conservation.
Collapse
Affiliation(s)
- Gina Della Togna
- Universidad Interamericana de Panama, Dirección de Investigación, Campus Central, Avenida Ricardo J. Alfaro, Panama; Smithsonian Tropical Research Institute, Panama Amphibian Rescue and Conservation Project, Panama.
| | - Lachlan G Howell
- University of Newcastle, Conservation Biology Research Group, University Drive, Callaghan, NSW, 2308, Australia
| | - John Clulow
- University of Newcastle, Conservation Biology Research Group, University Drive, Callaghan, NSW, 2308, Australia
| | | | - Ruth Marcec-Greaves
- National Amphibian Conservation Center, Detroit Zoological Society, Royal Oak, MI, 48067, USA
| | - Natalie E Calatayud
- San Diego Zoo Institute for Conservation Research, San Pasqual Valley Road, Escondido, CA, 92027, USA; Taronga Institute of Science and Learning, Taronga Conservation Society Australia, Taronga Western Plains Zoo, Dubbo, NSW, 2830, Australia
| |
Collapse
|
13
|
Wu M, Wu D, Hu C, Yan C. How to Make a Cost Model for the Birth Cohort Biobank in China. Front Public Health 2020; 8:24. [PMID: 32154203 PMCID: PMC7046621 DOI: 10.3389/fpubh.2020.00024] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2019] [Accepted: 01/24/2020] [Indexed: 11/13/2022] Open
Abstract
Biobanks and cohort studies are a popular topic in China these days and even in the global scientific research field. Cohorts with biological material are necessary to investigate potential biological mechanisms behind a disease and its early detection. Establishing a biobank is expensive and the long-term sustainability of biorepositories is a key issue globally. There is some published information on tools to calculate the biospecimen user fee; however, they may not be suitable for China's biobanks (as most of the biobanks in China are not for profit and are funded by government or research grants, and as such, funding is a major constraint). The limited published data also tend to be highly variable and specific to the type of biobank. The authors of this article aim to present the basis of a cost analysis model for a biobank of human biological samples of a birth cohort in Shanghai, China. The results show that it is very practical for us to consider how to build a cost model for the birth cohort biobank from the direct funds, such as storage equipment, temperature monitoring system, information management system, and so on. We conclude that by comparing the similarities and differences between China's cost model and that of other countries, this paper provides valuable information for biobankers to identify new perspectives on potential collaborators and mutual learning opportunities.
Collapse
Affiliation(s)
- Meiqin Wu
- MOE, Shanghai Key Laboratory of Children's Environmental Health, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
| | - Deqing Wu
- Department of Gastroenterology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China
| | - Chunping Hu
- School of Public Health, Shanghai Jiao Tong University, Shanghai, China
| | - Chonghuai Yan
- MOE, Shanghai Key Laboratory of Children's Environmental Health, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
| |
Collapse
|
14
|
Fernández IC, Merino IG, Muñoz-Fernández MÁ. Assessing and measuring financial sustainability model of the Spanish HIV HGM BioBank. J Transl Med 2020; 18:6. [PMID: 31907070 PMCID: PMC6943905 DOI: 10.1186/s12967-019-02187-w] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2019] [Accepted: 12/23/2019] [Indexed: 12/20/2022] Open
Abstract
Background The Spanish HIV HGM BioBank is of great relevance for basic and clinical investigation, and for those groups trying to establish large networks focused on investigation on specific clinical problems. The collection of different types of samples from HIV-infected individuals is the beginning of the chain of translational investigation, starting in 2004 a prospective national HIV BioBank that expanded in 2009 a local node (HGM: Hospital Gregorio Marañón) for diverse pathologies and clinical networks, not only in adults but also in paediatric patients, becoming the Spanish HIV HGM BioBank. Our main objective is to find a general criteria and analytical tools to widespread its economic management to assure their sustainability and the future exploitation of the extreme high valuable biomaterial they custody. Methods The Spanish HIV HGM BioBank was created with the aim of contributing to advance understanding of different pathologies through the transfer, management, register, processing, cryopreservation and cession of biological material from patients, always for research purposes and under conditions that guarantee its usefulness in current studies and future research that may appear as knowledge evolves. In this study, we have developed a policy for financial control and recovery costs of the Spanish HIV HGM BioBank. Results Actually, Spanish HIV HGM BioBank guards 413,747 vials of 46,594 samples from 16,210 donors with various prospective longitudinal study type of samples. Interestingly, more than 7907 of these samples are now used in 28 national and international investigation projects and clinical trials. One of the objectives of this study is to develop an economic plan that you get future projects, design of acceptance or rejection keys, have internal investment limits, minimum recovery needs in short/medium term, deviation detection system and a register of capital recovery by period and type of service for the Spanish HIV HGM BioBank. Conclusion Our model can help BioBanks that do not have a costs recovery model to design it, as well as to detect improves and functional revisions to those experienced in this field.
Collapse
Affiliation(s)
- Irene Consuegra Fernández
- Immunology Section, Molecular ImmunoBiology Laboratory, Hospital General Universitario Gregorio Marañón and Instituto Investigación Sanitaria Gregorio Marañón, C/Doctor Esquerdo 46, 28007, Madrid, Spain.,Spanish HIV HGM BioBank, Madrid, Spain.,Networking Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Instituto de Salud Carlos III, 28029, Madrid, Spain
| | - Isabel García Merino
- Immunology Section, Molecular ImmunoBiology Laboratory, Hospital General Universitario Gregorio Marañón and Instituto Investigación Sanitaria Gregorio Marañón, C/Doctor Esquerdo 46, 28007, Madrid, Spain.,Spanish HIV HGM BioBank, Madrid, Spain.,Networking Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Instituto de Salud Carlos III, 28029, Madrid, Spain
| | - María Ángeles Muñoz-Fernández
- Immunology Section, Molecular ImmunoBiology Laboratory, Hospital General Universitario Gregorio Marañón and Instituto Investigación Sanitaria Gregorio Marañón, C/Doctor Esquerdo 46, 28007, Madrid, Spain. .,Spanish HIV HGM BioBank, Madrid, Spain. .,Networking Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Instituto de Salud Carlos III, 28029, Madrid, Spain.
| |
Collapse
|
15
|
Linsen L, Vanhees K, Vanoppen E, Ulenaers K, Driessens S, Penders J, Somers V, Stinissen P, Rummens JL. Raising to the Challenge: Building a Federated Biobank to Accelerate Translational Research-The University Biobank Limburg. Front Med (Lausanne) 2019; 6:224. [PMID: 31750305 PMCID: PMC6842921 DOI: 10.3389/fmed.2019.00224] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2019] [Accepted: 09/30/2019] [Indexed: 12/12/2022] Open
Abstract
Irreproducibility of research results is one of the major contributing factors to the failure of translating basic research results into tangible bedside progress. To address this, the University Biobank Limburg (UBiLim) was founded by a collaboration between Hasselt University, the Hospital East-Limburg, and the Jessa Hospital. This paper describes the evolution of this process and the barriers encountered on the way. UBiLim evolved from an archival collection over a single-site biobank into a federated structure, supporting translational research at the founding institutions. Currently, UBiLim is a federated biobank, with an established organizational structure and processing, and storage facilities at each of the three sites. All activities are integrated in an ISO15189-accredited Quality Management System and based on (inter)national biobank guidelines. Common methods for processing and storage of a plethora of sample types, suitable for state-of-the-art applications, were validated and implemented. Because the biobank is embedded in two hospitals, the request of researchers to include certain sample types or enroll specific patient groups can quickly be met. Funding has been a major challenge in each step of its evolution and remains the biggest issue for long-term biobank sustainability. To a lesser extent, the Belgian legislation and the operational cost of information management system are also concerns for smooth biobank operations. Nonetheless, UBiLim serves as a facilitator and accelerator for translational research in the Limburg area of Belgium that, given the fields of research, may have an impact on international patient care.
Collapse
Affiliation(s)
- Loes Linsen
- University Biobank Limburg (UBiLim), Hasselt, Belgium.,Faculty of Medicine and Life Sciences, Limburg Clinical Research Center, Hasselt University, Diepenbeek, Belgium.,Clinical Laboratory, Jessa Hospital, Hasselt, Belgium
| | - Kimberly Vanhees
- University Biobank Limburg (UBiLim), Hasselt, Belgium.,Faculty of Medicine and Life Sciences, Limburg Clinical Research Center, Hasselt University, Diepenbeek, Belgium.,Clinical Laboratory, Jessa Hospital, Hasselt, Belgium
| | - Evi Vanoppen
- University Biobank Limburg (UBiLim), Hasselt, Belgium.,Clinical Laboratory, Jessa Hospital, Hasselt, Belgium
| | - Kim Ulenaers
- University Biobank Limburg (UBiLim), Hasselt, Belgium.,Faculty of Medicine and Life Sciences, Biomedical Research Institute, Hasselt University, Diepenbeek, Belgium
| | - Suzanne Driessens
- University Biobank Limburg (UBiLim), Hasselt, Belgium.,Clinical Laboratory, Hospital East-Limburg (ZOL), Genk, Belgium
| | - Joris Penders
- University Biobank Limburg (UBiLim), Hasselt, Belgium.,Faculty of Medicine and Life Sciences, Limburg Clinical Research Center, Hasselt University, Diepenbeek, Belgium.,Clinical Laboratory, Hospital East-Limburg (ZOL), Genk, Belgium
| | - Veerle Somers
- University Biobank Limburg (UBiLim), Hasselt, Belgium.,Faculty of Medicine and Life Sciences, Biomedical Research Institute, Hasselt University, Diepenbeek, Belgium
| | - Piet Stinissen
- University Biobank Limburg (UBiLim), Hasselt, Belgium.,Faculty of Medicine and Life Sciences, Biomedical Research Institute, Hasselt University, Diepenbeek, Belgium
| | - Jean-Luc Rummens
- University Biobank Limburg (UBiLim), Hasselt, Belgium.,Faculty of Medicine and Life Sciences, Limburg Clinical Research Center, Hasselt University, Diepenbeek, Belgium.,Clinical Laboratory, Jessa Hospital, Hasselt, Belgium
| |
Collapse
|
16
|
Rao A, Vaught J, Tulskie B, Olson D, Odeh H, McLean J, Moore HM. Critical Financial Challenges for Biobanking: Report of a National Cancer Institute Study. Biopreserv Biobank 2019; 17:129-138. [PMID: 30638412 DOI: 10.1089/bio.2018.0069] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023] Open
Abstract
BACKGROUND Researchers and other key stakeholders in biobanking often do not have a thorough understanding of the true costs and challenges associated with initiating, running, and maintaining a biobank. The National Cancer Institute's Biorepositories and Biospecimen Research Branch (BBRB) commissioned the Biobanking Financial Sustainability survey to better understand the challenges that biobanks face in supporting ongoing operations. A series of interviews with biobanking managers and an international focus group session informed the content of the survey. METHODS The design of the survey included five main sections, each containing questions related to primary topics as follows: general demographics, operations, funding sources, costs, and financial challenges. While the survey focused on financial issues and challenges, it also explored staffing and strategic planning as these issues relate to the sustainability of operations and financial support. U.S. and international biobanks were included in the survey. RESULTS Biobanks in general are dependent on public funding and most biobanks do not have formal plans for the long-term stewardship of their collections. Respondents are working at a critical level of personnel and are not in a position to further reduce staffing. Smaller biobanks in particular need assistance in defining reasonable cost recovery user fees for biospecimens and related services. CONCLUSIONS The survey results highlight several issues that are important for long-term biobank sustainability. It is critical to prepare for such issues as effective biobanking practices have increasingly been recognized as a key component for the advancement of precision medicine.
Collapse
Affiliation(s)
- Abhi Rao
- 1 Biorepositories and Biospecimen Research Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
| | - Jim Vaught
- 2 Editor-in-Chief, Biopreservation and Biobanking
| | - Bill Tulskie
- 3 Life Data Systems, Inc., Gaithersburg, Maryland
| | - Dorie Olson
- 3 Life Data Systems, Inc., Gaithersburg, Maryland
| | - Hana Odeh
- 1 Biorepositories and Biospecimen Research Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
| | | | - Helen M Moore
- 1 Biorepositories and Biospecimen Research Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
| |
Collapse
|
17
|
Henderson MK, Goldring K, Simeon-Dubach D. Advancing Professionalization of Biobank Business Operations: A Worldwide Survey. Biopreserv Biobank 2018; 17:71-75. [PMID: 30412417 DOI: 10.1089/bio.2018.0079] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Quality specimens from biobanks are key resources to support reproducible research. Sustaining biobanks requires robust management. We recently published a pilot survey that indicated that over half the participating biobanks had business plans in place and another third were working on business planning. While the results provided a clue to the status of business planning in biobanking, it was concluded that a longer and more in-depth survey and analysis were required. In April 2017, an extended survey was distributed worldwide in English, French, Chinese, German, and Spanish, through multiple channels. The survey was built using the Survey Monkey tool. Our hypothesis was that those biobanks that already have a business plan also have a more professional management structure. The questions were designed to understand more details about each biobank's business operations and communications. A total of 276 biobanks participated (China 65, France 40, United States 34, Spain 27, Germany 24, Australia 23, and rest of the world 63). About two thirds of the biobanks were established in the last 10 years. The responses provided data on the size of biobanks answering the survey, their status of business planning, and how and through what mediums they are communicating with customers. Biobanks with a business plan or preparing to have one showed a clear trend of having a customer strategy for marketing the samples and communicating with customers. No trend could be seen regarding websites and activities in social media. We confirmed our hypothesis that biobanks that have or are in the process of preparing a business plan are showing a trend toward more professional structures. In the biobanking community, the business mind-set and use of the business plan as a management tool have not quite arrived.
Collapse
Affiliation(s)
- Marianne K Henderson
- 1 National Cancer Institute, National Institutes of Health (NIH), Rockville, Maryland
| | - Kirstin Goldring
- 2 Sample Management, Discovery Science, IMED Biotech Unit, AstraZeneca, Cambridge, United Kingdom
| | | |
Collapse
|
18
|
Macheiner T, Huppertz B, Bayer M, Sargsyan K. Challenges and Driving Forces for Business Plans in Biobanking. Biopreserv Biobank 2017; 15:121-125. [PMID: 28338345 DOI: 10.1089/bio.2017.0018] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
BACKGROUND Due to increased utilization of biospecimens for research and emergence of new technologies, the availability and quality of biospecimens and their collection are coming more and more into focus. However, the long-term economic situation of biobanks is still mostly unclear. Also, the common sustainable utilization of various international biobanks is challenging due to local differences in sample processing, law and ethics. AIM This article discusses possible strategies to achieve a sustainable utilization of biospecimens as part of the business plan of biobanks. METHODS The following questions were addressed as part of a business plan: (1) How can a biobank build up and maintain an up-to-date infrastructure? (2) What kind of funding can support the sustainability of a biobank? (3) Is there an international solution for informed consents to enable sample and data sharing? (4) How can a biobank react during economically unstable periods? (5) Which kind of biobanking research is innovative? (6) What kind of education could be most needful for knowledge transfer in biobanking? (7) Does an expiration date for a biobank make sense according to the period of funding? CONCLUSION A strategy for optimal utilization begins with sharing of resources, infrastructure, and investments at the planning stage of a biobank, and continues to the transfer of knowledge and know-how by education. For clinical biobanks in particular, a long-term funding and cost recovery strategy is necessary for sustainable utilization.
Collapse
|
19
|
Ciaburri M, Napolitano M, Bravo E. Business Planning in Biobanking: How to Implement a Tool for Sustainability. Biopreserv Biobank 2016; 15:46-56. [PMID: 27898226 PMCID: PMC5327055 DOI: 10.1089/bio.2016.0045] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
Abstract
Worldwide, the sustainability of public health systems is challenged by the increasing number and cost of personalized therapies. Quality biological samples stored in biobanks are essential for the provision of appropriate health services and also act as a reservoir for the development of precision medicine and biotechnological innovation. Economic sustainability is a crucial factor in the maintenance of biobanking activities. Traditionally, management of biobanking is performed by health researchers and/or clinicians whose knowledge of economic issues is inadequate. On the other hand, familiarity with financial instruments used by economists is not often accompanied by a consolidated understanding of biobanking features. This article aims to be a guide for the implementation of business plans in biobanking and proposes models for the facilitation of their preparation, thus contributing to recognition of the importance of efficient management of resources of public health services.
Collapse
Affiliation(s)
- Mirella Ciaburri
- 1 Department of Management, University LUISS Guido Carli , Rome, Italy .,2 Departments of Haematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità , Rome, Italy
| | - Mariarosaria Napolitano
- 2 Departments of Haematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità , Rome, Italy
| | - Elena Bravo
- 2 Departments of Haematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità , Rome, Italy
| |
Collapse
|
20
|
Henderson MK, Goldring K, Simeon-Dubach D. Achieving and Maintaining Sustainability in Biobanking Through Business Planning, Marketing, and Access. Biopreserv Biobank 2016; 15:1-2. [PMID: 27860502 DOI: 10.1089/bio.2016.0083] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023] Open
|
21
|
Matzke LAM, Babinszky S, Slotty A, Meredith A, Castillo-Pelayo T, Henderson MK, Simeon-Dubach D, Schacter B, Watson PH. Biospecimen User Fees: Global Feedback on a Calculator Tool. Biopreserv Biobank 2016; 15:57-64. [PMID: 27576065 DOI: 10.1089/bio.2016.0027] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022] Open
Abstract
The notion of attributing user fees to researchers for biospecimens provided by biobanks has been discussed frequently in the literature. However, the considerations around how to attribute the cost for these biospecimens and data have, until recently, not been well described. Common across most biobank disciplines are similar factors that influence user fees such as capital and operating costs, internal and external demand, and market competition. A biospecimen user fee calculator tool developed by CTRNet, a tumor biobank network, was published in 2014 and is accessible online at www.biobanking.org . The next year a survey was launched that tested the applicability of this user fee tool among a global health research biobank user base, including both cancer and noncancer biobanking. Participants were first asked to estimate user fee pricing for three hypothetical user scenarios based on their biobanking experience (estimated pricing) and then to calculate fees for the same scenarios using the calculator tool (calculated pricing). Results demonstrated variation in estimated pricing that was reduced by calculated pricing. These results are similar to those found in a similar previous study restricted to a group of Canadian tumor biobanks. We conclude that the use of a biospecimen user fee calculator contributes to reduced variation of user fees and for biobank groups (e.g., biobank networks), could become an important part of a harmonization strategy.
Collapse
Affiliation(s)
- Lise A M Matzke
- 1 Department of Pathology and Laboratory Medicine, Office of Biobank Education and Research (OBER), University of British Columbia , Vancouver, Canada
| | - Sindy Babinszky
- 2 Tumour Tissue Repository (TTR), BC Cancer Agency , Vancouver Island Centre, Victoria, Canada
| | - Alex Slotty
- 1 Department of Pathology and Laboratory Medicine, Office of Biobank Education and Research (OBER), University of British Columbia , Vancouver, Canada
| | - Anna Meredith
- 1 Department of Pathology and Laboratory Medicine, Office of Biobank Education and Research (OBER), University of British Columbia , Vancouver, Canada
| | - Tania Castillo-Pelayo
- 2 Tumour Tissue Repository (TTR), BC Cancer Agency , Vancouver Island Centre, Victoria, Canada
| | | | | | - Brent Schacter
- 5 Canadian Tissue Repository Network, CancerCare Manitoba, Winnipeg, Canada
| | - Peter H Watson
- 1 Department of Pathology and Laboratory Medicine, Office of Biobank Education and Research (OBER), University of British Columbia , Vancouver, Canada .,2 Tumour Tissue Repository (TTR), BC Cancer Agency , Vancouver Island Centre, Victoria, Canada .,5 Canadian Tissue Repository Network, CancerCare Manitoba, Winnipeg, Canada
| |
Collapse
|
22
|
Watson PH. Biospecimen Complexity-the Next Challenge for Cancer Research Biobanks? Clin Cancer Res 2016; 23:894-898. [PMID: 27551001 DOI: 10.1158/1078-0432.ccr-16-1406] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/19/2016] [Revised: 08/08/2016] [Accepted: 08/09/2016] [Indexed: 11/16/2022]
Abstract
Purpose: Biospecimens (e.g., tissues, bloods, fluids) are critical for translational cancer research to generate the necessary knowledge to guide implementation of precision medicine. Rising demand and the need for higher quality biospecimens are already evident.Experimental Design: The recent increase in requirement for biospecimen complexity in terms of linked biospecimen types, multiple preservation formats, and longitudinal data was explored by assessing trends in cancer research publications from 2000 to 2014.Results: A PubMed search shows that there has been an increase in both raw numbers and the relative proportion (adjusted for total numbers of articles in each period) of the subgroups of articles typically associated with the use of biospecimens and both dense treatment and/or outcomes data and multiple biospecimen formats.Conclusions: Increasing biospecimen complexity is a largely unrecognized and new pressure on cancer research biobanks. New approaches to cancer biospecimen resources are needed such as the implementation of more efficient and dynamic consent mechanisms, stronger participant involvement in biobank governance, development of requirements for registration of collections, and models to establish stock targets for biobanks. In particular, the latter two approaches would enable funders to establish a better balance between biospecimen supply and research demand, reduce expenditure on duplicate collections, and encourage increased efficiency of biobanks to respond to the research need for more complex cases. This in turn would also enable biobanks to focus more on quality and standardization that are surely factors in the even more important arena of research reproducibility. Clin Cancer Res; 23(4); 894-8. ©2016 AACR.
Collapse
Affiliation(s)
- Peter H Watson
- Trev and Joyce Deeley Research Centre, British Columbia Cancer Agency, Victoria, British Columbia, Canada. .,Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada
| |
Collapse
|